Browsing ICR Divisions by author "Gao, Qiong"
Now showing items 1-20 of 24
-
An In Vivo Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer.
Ashenden, M; van Weverwijk, A; Murugaesu, N; Fearns, A; Campbell, J; et al. (AMER ASSOC CANCER RESEARCH, 2017-09-01)Chemotherapy remains the mainstay of treatment for advanced breast cancer; however, resistance is an inevitable event for the majority of patients with metastatic disease. Moreover, there is little information available ... -
Changes in expression of hormone-regulated and proliferation-associated genes across the menstrual cycle in oestrogen receptor-positive breast cancer
Haynes, BP; Ginsburg, O; Gao, Q; Folkerd, E; Afentakis, M; et al. (SPRINGER, 2020-04-01) -
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala, N; Gao, Q; Pancholi, S; Roberg-Larsen, H; Zvelebil, M; et al. (BMC, 2016-06-01)BACKGROUND: Therapies targeting estrogenic stimulation in estrogen receptor-positive (ER+) breast cancer (BC) reduce mortality, but resistance remains a major clinical problem. Molecular studies have shown few high-frequency ... -
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
Pancholi, S; Leal, MF; Ribas, R; Simigdala, N; Schuster, E; et al. (BMC, 2019-12-04)BACKGROUND: Endocrine therapies are still the main strategy for the treatment of oestrogen receptor-positive (ER+) breast cancers (BC), but resistance remains problematic. Cross-talk between ER and PI3K/AKT/mTORC has been ... -
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
Tucker, ER; Jiménez, I; Chen, L; Bellini, A; Gorrini, C; et al. (AMER ASSOC CANCER RESEARCH, 2023-04-03)PURPOSE: ALK-activating mutations are identified in approximately 10% of newly diagnosed neuroblastomas and ALK amplifications in a further 1%-2% of cases. Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) ... -
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Martin, L-A; Ribas, R; Simigdala, N; Schuster, E; Pancholi, S; et al. (NATURE PORTFOLIO, 2017-11-30)Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show increased prevalence in the metastatic, ... -
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Morandi, A; Martin, L-A; Gao, Q; Pancholi, S; Mackay, A; et al. (AMER ASSOC CANCER RESEARCH, 2013-06-15)Most breast cancers at diagnosis are estrogen receptor-positive (ER(+)) and depend on estrogen for growth and survival. Blocking estrogen biosynthesis by aromatase inhibitors has therefore become a first-line endocrine ... -
Generation and characterisation of two D2A1 mammary cancer sublines to model spontaneous and experimental metastasis in a syngeneic BALB/c host.
Jungwirth, U; van Weverwijk, A; Melake, MJ; Chambers, AF; Gao, Q; et al. (COMPANY BIOLOGISTS LTD, 2018-01-18)Studying the complex mechanisms underlying breast cancer metastasis and therapy response necessitates relevant in vivo models, particularly syngeneic models with an intact immune system. Two syngeneic spontaneously metastatic ... -
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
López-Knowles, E; Gao, Q; Cheang, MCU; Morden, J; Parker, J; et al. (BIOMED CENTRAL LTD, 2016-04-01)BACKGROUND: Gene expression is widely used for the characterisation of breast cancers. Variability due to tissue heterogeneity or measurement error or systematic change due to peri-surgical procedures can affect measurements ... -
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Gao, Q; López-Knowles, E; Cheang, MCU; Morden, J; Ribas, R; et al. (BMC, 2019-12-31)BACKGROUND: Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. In this study, we sought to investigate the impact of aromatase inhibitor (AI) therapy on gene expression ... -
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
Gellert, P; Segal, CV; Gao, Q; López-Knowles, E; Martin, L-A; et al. (NATURE PORTFOLIO, 2016-11-09)Pre-surgical studies allow study of the relationship between mutations and response of oestrogen receptor-positive (ER+) breast cancer to aromatase inhibitors (AIs) but have been limited to small biopsies. Here in phase I ... -
Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis.
Jungwirth, U; van Weverwijk, A; Evans, RJ; Jenkins, L; Vicente, D; et al. (NATURE PORTFOLIO, 2021-06-10)Profiling studies have revealed considerable phenotypic heterogeneity in cancer-associated fibroblasts (CAFs) present within the tumour microenvironment, however, functional characterisation of different CAF subsets is ... -
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.
Gao, Q; López-Knowles, E; U Cheang, MC; Morden, J; Ribas, R; et al. (OXFORD UNIV PRESS, 2018-05-22)To investigate the impact of sampling methodology on gene expression data from primary estrogen receptor-positive (ER+) breast cancer biopsies, global gene expression was measured in core-cut biopsies at baseline and surgery ... -
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer.
Haynes, BP; Ginsburg, O; Gao, Q; Folkerd, E; Afentakis, M; et al. (NATURE PUBLISHING GROUP, 2019-11-15)The major changes in hormone levels that occur through the menstrual cycle have been postulated to affect the expression of hormone-regulated and proliferation-associated genes (PAGs) in premenopausal ER+ breast cancer. ... -
Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation.
van Weverwijk, A; Koundouros, N; Iravani, M; Ashenden, M; Gao, Q; et al. (NATURE PUBLISHING GROUP, 2019-06-20)The different stages of the metastatic cascade present distinct metabolic challenges to tumour cells and an altered tumour metabolism associated with successful metastatic colonisation provides a therapeutic vulnerability ... -
MoKCa database--mutations of kinases in cancer.
Richardson, CJ; Gao, Q; Mitsopoulous, C; Zvelebil, M; Pearl, LH; et al. (OXFORD UNIV PRESS, 2009-01-01)Members of the protein kinase family are amongst the most commonly mutated genes in human cancer, and both mutated and activated protein kinases have proved to be tractable targets for the development of new anticancer ... -
Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy.
Haynes, BP; Ginsburg, O; Gao, Q; Folkerd, E; Afentakis, M; et al. (NATURE PUBLISHING GROUP, 2017-11-27)For premenopausal women with primary ER + breast cancer, oophorectomy (OvX) is an evidence-based cost-effective option and is standard treatment in many countries. However, there is virtually no data describing the effects ... -
Mouse mammary stem cells express prognostic markers for triple-negative breast cancer.
Soady, KJ; Kendrick, H; Gao, Q; Tutt, A; Zvelebil, M; et al. (BMC, 2015-03-04)INTRODUCTION: Triple-negative breast cancer (TNBC) is a heterogeneous group of tumours in which chemotherapy, the current mainstay of systemic treatment, is often initially beneficial but with a high risk of relapse and ... -
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Buus, R; Yeo, B; Brentnall, AR; Klintman, M; Cheang, MCU; et al. (2018-09-04)Background Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0-5-year and 5-10-year ... -
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Buus, R; Yeo, B; Brentnall, AR; Klintman, M; Cheang, MCU; et al. (BMC, 2018-09-04)BACKGROUND: Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0-5-year and 5-10-year ...